Milrinone is a phosphodiesterase-3 (PDE3) inhibitor used for short-term cardiac support in patients with acute decompensated heart failure, pulmonary hypertension, or chronic heart failure. It works by enhancing cardiac contractility (inotropy), improving relaxation (lusitropy), and inducing vasodilation.
Parent: Milrinone
Impurities in Milrinone can develop during its synthesis, formulation, and storage. These must be closely monitored to ensure drug safety and efficacy.
Analytical Techniques for Impurity Detection
Fourier Transform Infrared Spectroscopy (FT-IR)
Milrinone is used in heart failure management by increasing heart muscle contraction (inotropic effect), improving relaxation, and dilating blood vessels to reduce cardiac workload.
Milrinone is a vasodilator. It reduces vascular resistance and lowers blood pressure, making it different from vasopressors, which increase blood pressure.
Milrinone works by inhibiting phosphodiesterase-3 (PDE3), leading to an increase in cyclic AMP (cAMP) levels. This enhances calcium availability in heart muscle cells, improving contractility and promoting vasodilation.
No, Milrinone and Dobutamine are both inotropic agents, but they work differently:
